OPKO Pharmaceuticals, LLC.
OPKO Renal, a division of OPKO Health, Inc., is committed to developing products that transform the standard of care in nephrology. OPKO develops proprietary products to treat secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). Our lead product, Rayaldee®, is indicated for the treatment of secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease and total blood levels of less than 30 ng/mL 25-hydroxyvitamin D.